86 results on '"Tewari, Krishnansu S."'
Search Results
2. Final survival analysis of topotecan and paclitaxel for first-line treatment of advanced cervical cancer: An NRG oncology randomized study.
- Author
-
Tewari, Krishnansu S., Sill, Michael W., Birrer, Michael J., Penson, Richard T., Huang, Helen, Moore, David H., Ramondetta, Lois M., Landrum, Lisa M., Oaknin, Ana, Reid, Thomas J., Leitao, Mario M., Michael, Helen E., and Monk, Bradley J.
- Subjects
- *
CERVICAL cancer , *PACLITAXEL , *TOPOTECAN , *SURVIVAL analysis (Biometry) , *GYNECOLOGIC oncology , *PAP test - Abstract
To determine whether a non‑platinum chemotherapy doublet improves overall survival (OS) among patients with recurrent/metastatic cervical carcinoma. Gynecologic Oncology Group protocol 240 is a phase 3, randomized, open-label, clinical trial that studied the efficacy of paclitaxel 175 mg/m2 plus topotecan 0.75 mg/m2 days 1–3 (n = 223) vs cisplatin 50 mg/m2 plus paclitaxel 135 or 175 mg/m2 (n = 229), in 452 patients with recurrent/metastatic cervical cancer. Each chemotherapy doublet was also studied with and without bevacizumab (15 mg/kg). Cycles were repeated every 21 days until progression, unacceptable toxicity, or complete response. The primary endpoints were OS and the frequency and severity of adverse effects. We report the final analysis of OS. At the protocol-specified final analysis, median OS was 16.3 (cisplatin-paclitaxel backbone) and 13.8 months (topotecan-paclitaxel backbone) (HR 1.12; 95% CI, 0.91–1.38; p = 0.28). Median OS for cisplatin-paclitaxel and topotecan-paclitaxel was 15 vs 12 months, respectively (HR 1.10; 95% CI,0.82–1.48; p = 0.52), and for cisplatin-paclitaxel-bevacizumab and topotecan-paclitaxel-bevacizumab was 17.5 vs 16.2 months, respectively (HR 1.16; 95% CI, 0.86–1.56; p = 0.34). Among the 75% of patients in the study population previously exposed to platinum, median OS was 14.6 (cisplatin-paclitaxel backbone) vs 12.9 months (topotecan-paclitaxel backbone), respectively (HR 1.09; 95% CI, 0.86–1.38; p = 0.48). Post-progression survival was 7.9 (cisplatin-paclitaxel backbone) vs 8.1 months (topotecan-paclitaxel backbone) (HR 0.95; 95% CI, 0.75–1.19). Grade 4 hematologic toxicity was similar between chemotherapy backbones. Topotecan plus paclitaxel does not confer a survival benefit to women with recurrent/metastatic cervical cancer, even among platinum-exposed patients. Topotecan-paclitaxel should not be routinely recommended in this population. NCT00803062. • Topotecan plus paclitaxel is not superior to cisplatin plus paclitaxel for recurrent/metastatic cervical cancer. • Topotecan-paclitaxel plus bevacizumab is not superior to cisplatin-paclitaxel plus bevacizumab for cervical cancer. • The non‑platinum doublet, topotecan-paclitaxel, should not be routinely used for recurrent/metastatic cervical cancer. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
3. Health-related quality of life with pembrolizumab or placebo plus chemotherapy with or without bevacizumab for persistent, recurrent, or metastatic cervical cancer (KEYNOTE-826): a randomised, double-blind, placebo-controlled, phase 3 trial.
- Author
-
Monk, Bradley J, Tewari, Krishnansu S, Dubot, Coraline, Caceres, M Valeria, Hasegawa, Kosei, Shapira-Frommer, Ronnie, Salman, Pamela, Yañez, Eduardo, Gümüş, Mahmut, Hurtado de Mendoza, Mivael Olivera, Samouëlian, Vanessa, Castonguay, Vincent, Arkhipov, Alexander, Tekin, Cumhur, Li, Kan, Martin Nguyen, Allison, Monberg, Matthew J, Colombo, Nicoletta, and Lorusso, Domenica
- Subjects
- *
CLINICAL trials , *INTERACTIVE voice response (Telecommunication) , *QUALITY of life , *CERVICAL cancer , *BEVACIZUMAB - Abstract
In the KEYNOTE-826 study, the addition of the anti-PD-1 monoclonal antibody pembrolizumab to chemotherapy with or without bevacizumab improved overall survival and progression-free survival (primary endpoints) versus placebo plus chemotherapy with or without bevacizumab, with manageable toxicity, in patients with persistent, recurrent, or metastatic cervical cancer. In this Article, we report patient-reported outcomes (PROs) from KEYNOTE-826. KEYNOTE-826 is a multicentre, randomised, phase 3 trial in 151 cancer treatment centres in 19 countries. Eligible patients were aged 18 years or older with persistent, recurrent, or metastatic cervical cancer not previously treated with systemic chemotherapy (previous radiosensitising chemotherapy was allowed) and not amenable to curative treatment and had an Eastern Cooperative Oncology Group performance status of 0 or 1. Patients were randomly assigned (1:1) centrally by means of an interactive voice response system in a double-blind manner to receive either pembrolizumab 200 mg or placebo every 3 weeks intravenously for up to 35 cycles plus chemotherapy (paclitaxel 175 mg/m2 plus cisplatin 50 mg/m2 or carboplatin area under the curve 5 mg/mL per min, intravenously) with or without bevacizumab 15 mg/kg every 3 weeks intravenously. Randomisation (block size of 4) was stratified by metastatic disease at diagnosis, planned bevacizumab use, and PD-L1 combined positive score. Patients, investigators, and other study personnel involved in study treatment administration or clinical evaluation of patients were unaware of treatment group assignments. PRO instruments were the EORTC Quality-of-Life-Core 30 (QLQ-C30), the EORTC cervical cancer module (QLQ-CX24), and the EuroQol-5 dimension-5 level (EQ-5D-5L) visual analogue scale, each collected before treatment at cycles 1–14 and every other cycle thereafter. Primary endpoints were overall survival and progression-free survival per RECIST version 1.1 by investigator review. Change from baseline in QLQ-C30 global health status (GHS)–quality of life (QoL) was a prespecified secondary endpoint and was assessed in the PRO full analysis population (all patients who received at least one dose of study treatment and completed at least one post-baseline PRO assessment). Other PRO analyses were protocol-specified exploratory endpoints. The study is registered with ClinicalTrials.gov , NCT03635567 , and is ongoing. Between Nov 20, 2018, and Jan 31, 2020, of 883 patients screened, 617 were randomly assigned (pembrolizumab group, n=308; placebo group, n=309). 587 (95%) of 617 patients received at least one dose of study treatment and completed at least one post-baseline PRO assessment and were therefore included in the PRO analyses (pembrolizumab group, n=290; placebo group, n=297). Median follow-up was 22·0 months (IQR 19·1–24·4). At week 30, QLQ-C30 completion was 199 (69%) of 290 patients in the pembrolizumab group and 168 (57%) of 297 patients in the placebo group; compliance was 199 (94%) of 211 and 168 (90%) of 186, respectively. The least squares mean change in QLQ-C30 GHS–QoL score from baseline to week 30 was −0·3 points (95% CI −3·1 to 2·6) in the pembrolizumab group and −1·3 points (−4·2 to 1·7) in the placebo group, with a between-group difference in least squares mean change of 1·0 point (95% CI −2·7 to 4·7). Median time to true deterioration in GHS–QoL was not reached (NR; 95% CI 13·4 months–NR) in the pembrolizumab group and 12·9 months (6·6–NR) in the placebo group (hazard ratio 0·84 [95% CI 0·65–1·09]). 122 (42%) of 290 patients in the pembrolizumab group versus 85 (29%) of 297 in the placebo group had improved GHS–QoL at any time during the study (p=0·0003). Addition of pembrolizumab to chemotherapy with or without bevacizumab did not negatively affect health-related quality of life. Along with the efficacy and safety results already reported from KEYNOTE-826, these data support the benefit of pembrolizumab and the value of immunotherapy in patients with recurrent, persistent, or metastatic cervical cancer. Merck Sharp & Dohme. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
4. Immunotherapy plus chemoradiotherapy in cervical cancer management.
- Author
-
Tewari, Krishnansu S and Monk, Bradley J
- Subjects
- *
CERVICAL cancer , *IMMUNOTHERAPY , *CHEMORADIOTHERAPY - Published
- 2024
- Full Text
- View/download PDF
5. The current landscape of molecular profiling in the treatment of epithelial ovarian cancer.
- Author
-
Haunschild, Carolyn E. and Tewari, Krishnansu S.
- Subjects
- *
HEREDITARY cancer syndromes , *OVARIAN epithelial cancer , *CANCER genes , *BRCA genes , *GENETIC testing , *GENETIC counseling ,CANCER susceptibility - Abstract
• All women with ovarian cancer should be offered germline testing for BRCA mutations and other cancer susceptibility genes • Patients with deleterious BRCA mutations should be offered frontline maintenance therapy with a PARP inhibitor • Assays for homologous recombination deficiency may guide treatment options in patients without a deleterious BRCA mutation • Tumor molecular profiling may identify targeted therapies for off-label use in patients with limited treatment options Advances in next generation sequencing have allowed for rapid and economical germline and tumor genomic profiling. Targeted therapies based on molecular tumor profiling are now integrated into treatment guidelines for many solid tumors. In epithelial ovarian cancer, 50% of tumors possess damaging mutations in homologous recombination repair genes (aka homologous recombination deficiency or HRD) which includes the BRCA genes. Deleterious BRCA mutations and HRD have recently emerged as predictive biomarkers for the use of PARP inhibitors in ovarian cancer. Every patient with ovarian cancer must be referred for genetic counseling and germline testing for BRCA mutations. Multigene panel genetic testing may be more informative and cost-effective than limited testing of cancer susceptibility genes. Patients without a germline deleterious BRCA mutation must be assessed for a somatic BRCA mutation. Assays for HRD may help guide treatment options in women who do not have a BRCA mutation. Currently, all patients with a germline or somatic BRCA mutation should be offered upfront maintenance therapy with a PARP inhibitor. During May 2020, options for maintenance therapy with a PARP inhibitor were expanded to patients with HRD and HR-proficient tumors. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
6. Bevacizumab plus fosbretabulin in recurrent ovarian cancer: Overall survival and exploratory analyses of a randomized phase II NRG oncology/gynecologic oncology group study.
- Author
-
Tewari, Krishnansu S., Sill, Michael W., Coleman, Robert L., Aghajanian, Carol, Mannel, Robert, DiSilvestro, Paul A., Powell, Matthew, Randall, Leslie M., Farley, John, Rubin, Stephen C., and Monk, Bradley J.
- Subjects
- *
GYNECOLOGIC cancer , *BEVACIZUMAB , *GYNECOLOGIC oncology , *OVARIAN cancer , *PROPORTIONAL hazards models , *SURVIVAL analysis (Biometry) - Abstract
To explore the relationship between tumor size and response to combined anti-vascular targeted therapy using the anti-angiogenesis inhibitor, bevacizumab, and the tubulin-binding vascular disrupting agent, fosbretabulin. An exploratory, post-hoc analysis of the randomized phase II trial, Gynecologic Oncology Group-0186I, was performed. One hundred and seven patients with recurrent ovarian carcinoma, treated with up to 3 prior regimens, were randomized to bevacizumab 15 mg/kg body weight with or without intravenous fosbretabulin 60 mg/m2 body surface area every 21 days until progression or unacceptable toxicity. The primary analysis favored the combination (HR 0.69; 95% CI, 0.47–1.00; p =.049) [Monk BJ, et al. J Clin Oncol 2016;34:2279–86]. The Cox proportional hazards model was used to estimate the treatment effect in various subpopulations. With extended follow-up, the median PFS for bevacizumab plus fosbretabulin was 7.6 months as compared to 4.8 months with bevacizumab alone (HR 0.74; 90% CI, 0.54–1.02). Overall survival was similar in the experimental and control arms (25.2 vs 24.4 mos, respectively, HR 0.85; 90% CI, 0.59–1.22; p =.461). Eighty-one patients had measurable disease and median tumor size was 5.7 cm. In the ≤5.7 cm subgroup, the HR for progression or death was 0.77 (90% CI 0.45–1.31). Patients with tumors >5.7 cm (n = 40) had a HR for progression or death of 0.55; 90% CI, 0.32–0.96; p =.075). Although no significant survival benefit was observed , the trend showing a reduced HR for progression or death with increasing tumor size when fosbretabulin is added to bevacizumab compared to bevacizumab alone warrants further study. • Tumor vascular disrupting agents represent a novel anti-vascular strategy • Combined vascular disrupting agent plus anti-angiogenesis therapy may have activity in bulky, recurrent ovarian carcinoma • The combination appears to be tolerable in the subpopulations studied. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
7. Philip John DiSaia, MD: Available Light & The Origin of Storms.
- Author
-
Tewari, Krishnansu S. and Monk, Bradley J.
- Subjects
- *
ACADEMIC medical centers , *GYNECOLOGY , *OBSTETRICS , *ONCOLOGISTS , *VOCATIONAL guidance - Abstract
During a career, which spanned nearly 60 years, Professor Philip J. DiSaia (1937–2018) trailblazed a path forward in academic medicine, which would become the standard by which Departments of Obstetrics and Gynecology and Gynecologic Oncology Divisions and Cancer Centers would be measured throughout the United States, in Europe and Japan. Following his discovery of fetal warfarin syndrome as a resident, DiSaia would serve in the U.S. Navy and successfully compete for an American Cancer Society Grant that would fund his Fellowship in Gynecologic Oncology under the instruction of Dr Felix N. Rutledge at the MD Anderson Hospital and Tumor Institute in Houston, Texas. Dr DiSaia's goal to establish a traditional academic department was realized at the University of California, Irvine, where he remained active in an unprecedented, uninterrupted 42‐year run, training many outstanding obstetrician‐gynecologists and gynecologic oncologists, future Division Directors, Cancer Center Directors and Department Chairpersons. His dedication to the field and inexhaustible work ethic fueled his many successes in tumor immunology and the clinical trials of the National Cancer Institute's Gynecologic Oncology Group. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
8. Robotic surgery for gynecologic cancers: indications, techniques and controversies.
- Author
-
Clair, Kiran H. and Tewari, Krishnansu S.
- Subjects
- *
HEMORRHAGE risk factors , *ABDOMINAL surgery , *ELDER care , *CANCER chemotherapy , *COMBINED modality therapy , *CONVALESCENCE , *ENDOSCOPIC surgery , *FEMALE reproductive organ tumors , *ERGONOMICS , *LAPAROSCOPY , *MEDICAL technology , *MORBID obesity , *SURGICAL robots , *TREATMENT effectiveness ,SURGICAL complication risk factors - Abstract
Minimally invasive surgery for gynecologic cancers is associated with fewer postoperative complications including less blood loss and quicker recovery time compared to traditional laparotomy. The robotic platform has allowed patients access to minimally invasive surgery due to its increased utilization by gynecologic oncologists. Many surgeons have embraced the robotic platform due to its technological advances over traditional laparoscopy including high‐definition 3D optics, wristed instrumentation, camera stability and improved ergonomics. While robotic surgery continues as a mainstay in the management of gynecologic cancers, it remains controversial in regards to its cost effectiveness and more recently, its long‐term impact on clinical and oncologic outcomes. A strong component of the justification of this surgical platform is based on extrapolated data from traditional laparoscopy despite limited prospective randomized trials for robotic‐assisted surgery. In this review, we highlight the use of robotic surgery in the management of gynecologic cancers in special populations: fertility sparing patients, the morbidly obese, the elderly, and patients with a favorable response to neoadjuvant chemotherapy. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
9. Gynecologic cancer in pregnancy.
- Author
-
Korenaga, Travis-Riley K. and Tewari, Krishnansu S.
- Subjects
- *
GYNECOLOGIC cancer , *MOLAR pregnancy , *FETAL heart rate monitoring , *IMMUNE checkpoint inhibitors , *OBSTETRICS , *AMNIOTIC liquid , *VAGINAL cancer - Abstract
Cancer complicates 1 in 1000 pregnancies. Multidisciplinary consensus comprised of Gynecologic Oncology, Pathology, Neonatology, Radiology, Anesthesiology, Maternal Fetal Medicine, and Social Work should be convened. Pregnancy provides an opportunity for cervical cancer screening, with deliberate delays in treatment permissible for early stage carcinoma. Vaginal delivery is contraindicated in the presence of gross lesion(s) and radical hysterectomy with lymphadenectomy at cesarean delivery is recommended. Women with locally advanced and metastatic/recurrent disease should commence treatment at diagnosis with chemoradiation and systemic therapy, respectively; neoadjuvant chemotherapy to permit gestational advancement may be considered in select cases. Most adnexal masses are benign and resolve by the second trimester. Persistent, asymptomatic, benign-appearing masses can be managed conservatively; surgery, if indicated, is best deferred to 15–20 weeks, with laparoscopy preferable over laparotomy whenever possible. Benign and malignant germ cell tumors and borderline tumors are occasionally encountered, with unilateral adnexectomy and preservation of the uterus and contralateral ovary being the rule. Epithelial ovarian cancer is exceedingly rare. Ultrasonography and magnetic resonance imaging lack ionizing radiation and can be employed to evaluate disease extent. Tumor markers, including CA-125, AFP, LDH, inhibin-B, and even CEA and ßhCG may be informative. If required, chemotherapy can be administered following organogenesis during the second and third trimesters. Because platinum and other anti-neoplastic agents cross the placenta, chemotherapy should be withheld after 34 weeks to avoid neonatal myelosuppression. Bevacizumab, immune checkpoint inhibitors, and PARP inhibitors should be avoided throughout pregnancy. Although antenatal glucocorticoids to facilitate fetal pulmonary maturation and amniotic fluid index assessment can be considered, there is no demonstrable benefit of tocolytics, antepartum fetal heart rate monitoring, and/or amniocentesis. Endometrial, vulvar, and vaginal cancer in pregnancy are curiosities, although leiomyosarcoma and the dreaded twin fetus/hydatidiform mole have been reported. For gynecologic malignancies, pregnancy does not impart aggressive clinical behavior and/or worse prognosis • Cancer affects 1 in 1000 pregnancies. • Diagnostic workup for cancer must be carefully selected and interpreted in pregnancy. • Cervical cancer is the most common gynecologic malignancy diagnosed in pregnancy. • Surgery and chemotherapy can be appropriately used with preservation of pregnancy. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
10. Should adjuvant chemotherapy be formally studied among patients found to have pelvic lymph node metastases following radical hysterectomy with lymphadenectomy for early-stage cervical cancer?
- Author
-
Bujnak, Alyssa C. and Tewari, Krishnansu S.
- Subjects
- *
LYMPHADENECTOMY , *ADJUVANT chemotherapy , *CERVICAL cancer , *LYMPHATIC metastasis , *ADJUVANT treatment of cancer , *PROGNOSIS , *HYSTERECTOMY - Published
- 2021
- Full Text
- View/download PDF
11. Targeted treatment of advanced ovarian cancer: spotlight on rucaparib.
- Author
-
Pearre, Diana C and Tewari, Krishnansu S
- Subjects
- *
OVARIAN cancer , *CYTOREDUCTIVE surgery , *BRCA genes - Abstract
The last 2 years have ushered in a new era in ovarian cancer therapy with the US Food and Drug Administration's (FDA) approval of poly-ADP ribose polymerase (PARP) inhibitors (PARPi). One of the deadliest cancers that women experience, ovarian cancer, is most often diagnosed in advanced stages. Although cytoreductive surgery and (platinum/taxane-based) chemotherapy can place the majority of patients into remission, most will experience a relapse of their disease in their lifetime. This has led to studies exploring the benefits and efficacy of maintenance treatment. This review will briefly discuss the history of maintenance therapy as well as focus on the FDA's approval of rucaparib and its companion tumor profiling test, in the US. It will describe how women with deleterious mutations in the BRCA gene, through their inherent deficiency in homologous recombination, presented scientists with a target to exploit through a concept known as synthetic lethality. Not only did this lead to a targeted treatment for BRCA mutation carriers but for other patients with deficiencies in homologous recombination and, more broadly, also in platinum-sensitive patients. The focus of this review will be on rucaparib in the US, approved for both maintenance of platinum-sensitive recurrent ovarian cancer and treatment in the third-line setting and beyond. It has the broadest indication amongst the three PARPi in ovarian cancer. Furthermore, the ongoing trials using rucaparib in ovarian cancer and other disease types will be discussed. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
12. Therapeutic vaccination using HPV 16 E7 to eradicate CIN3.
- Author
-
Tewari, Krishnansu S.
- Subjects
- *
CONIZATION , *CERVICAL intraepithelial neoplasia , *GENITAL warts , *HUMAN papillomavirus vaccines , *HIGH dose rate brachytherapy - Published
- 2019
- Full Text
- View/download PDF
13. Cervical cancer – State of the science: From angiogenesis blockade to checkpoint inhibition.
- Author
-
Minion, Lindsey E. and Tewari, Krishnansu S.
- Subjects
- *
CERVICAL cancer treatment , *VASCULAR endothelial growth factors , *BEVACIZUMAB , *NEOVASCULARIZATION , *PROGRESSION-free survival - Abstract
Vascular endothelial growth factor (VEGF) has emerged as a therapeutic target in several malignancies, including cervical cancer. Chemotherapy doublets combined with the fully humanized monoclonal antibody, bevacizumab, now constitute first-line therapy for women struggling with recurrent/metastatic cervical carcinoma. Regulatory approval for this indication was based on the phase III randomized trial, GOG 240, which demonstrated a statistically significant and clinically meaningful improvement in overall survival when bevacizumab was added to chemotherapy: 17.0 vs 13.3 months; HR 0.71; 98% CI, 0.54–0.95; p = .004. Incorporation of bevacizumab resulted in significant improvements in progression-free survival and response. These benefits were not accompanied by deterioration in quality of life. GOG 240 identified vaginal fistula as a new adverse event associated with bevacizumab use. All fistulas occurred in women who had received prior pelvic radiotherapy, and none resulted in emergency surgery, sepsis, or death. Final protocol-specified analysis demonstrated continued separation of the survival curves favoring VEGF inhibition: 16.8 vs 13.3 months; HR 0.77; 95% CI, 0.62–9.95; p = .007. Post-progression survival was not significantly different between the arms in GOG 240. Moving forward, immunotherapy has now entered the clinical trial arena to address the high unmet clinical need for effective and tolerable second line therapies in this patient population. Targeting the programmed cell death 1/programmed death ligand 1 (PD-1/PD-L1) pathway using checkpoint inhibitors to break immunologic tolerance is promising. The immunologic landscape involving human papillomavirus-positive head and neck carcinoma and cutaneous squamous cell carcinoma can be informative when considering feasibility of checkpoint blockade in advanced cervical cancer. Phase II studies using anti-PD-1 molecules, nivolumab and pembrolizumab are ongoing, and GOG 3016, the first phase III randomized trial of a checkpoint inhibitor (cemiplimab) in cervical cancer, recently activated. Important considerations in attempts to inhibit the inhibitors include pseudoprogression and post-progression survival, abscopal effects, and immune-related adverse events, including endocrinopathies. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
14. Recent breakthroughs in the management of locally advanced and recurrent/metastatic cervical cancer.
- Author
-
García, Eduardo, Ayoub, Natalie, and Tewari, Krishnansu S.
- Subjects
- *
CERVICAL cancer , *METASTASIS , *POOR communities , *THERAPEUTICS , *REGULATORY approval - Abstract
Cervical cancer continues to be a global threat affecting individuals in resource poor communities disproportionately. The treatment paradigm for this disease is ever evolving with recent innovations propelling oncologic outcomes to a new frontier offering survival benefits for patients struggling with locally advanced disease and metastatic/recurrent carcinoma. Immunologic checkpoint inhibitors and anti-body drug conjugates represent two novel drug classes that have demonstrable activity in this disease, particularly in the first-line and second-line treatment paradigm for recurrence. The tolerability of these novel medicines and associated durable responses underscore regulatory approval by the U.S. Food and Drug Administrations and their implementation in clinic. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
15. Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240).
- Author
-
Tewari, Krishnansu S., Sill, Michael W., Penson, Richard T., Helen Huang, Ramondetta, Lois M., Landrum, Lisa M., Oaknin, Ana, Reid, Thomas J., Leitao, Mario M., Michael, Helen E., DiSaia, Philip J., Copeland, Larry J., Creasman, William T., Stehman, Frederick B., Brady, Mark F., Burger, Robert A., Thigpen, J. Tate, Birrer, Michael J., Waggoner, Steven E., and Moore, David H.
- Subjects
- *
BEVACIZUMAB , *CERVICAL cancer treatment , *ADVERSE health care events , *DRUG administration , *RANDOMIZED controlled trials - Abstract
Background: On Aug 14, 2014, the US Food and Drug Administration approved the antiangiogenesis drug bevacizumab for women with advanced cervical cancer on the basis of improved overall survival (OS) after the second interim analysis (in 2012) of 271 deaths in the Gynecologic Oncology Group (GOG) 240 trial. In this study, we report the prespecified final analysis of the primary objectives, OS and adverse events.Methods: In this randomised, controlled, open-label, phase 3 trial, we recruited patients with metastatic, persistent, or recurrent cervical carcinoma from 81 centres in the USA, Canada, and Spain. Inclusion criteria included a GOG performance status score of 0 or 1; adequate renal, hepatic, and bone marrow function; adequately anticoagulated thromboembolism; a urine protein to creatinine ratio of less than 1; and measurable disease. Patients who had received chemotherapy for recurrence and those with non-healing wounds or active bleeding conditions were ineligible. We randomly allocated patients 1:1:1:1 (blocking used; block size of four) to intravenous chemotherapy of either cisplatin (50 mg/m2 on day 1 or 2) plus paclitaxel (135 mg/m2 or 175 mg/m2 on day 1) or topotecan (0·75 mg/m2 on days 1-3) plus paclitaxel (175 mg/m2 on day 1) with or without intravenous bevacizumab (15 mg/kg on day 1) in 21 day cycles until disease progression, unacceptable toxic effects, voluntary withdrawal by the patient, or complete response. We stratified randomisation by GOG performance status (0 vs 1), previous radiosensitising platinum-based chemotherapy, and disease status (recurrent or persistent vs metastatic). We gave treatment open label. Primary outcomes were OS (analysed in the intention-to-treat population) and adverse events (analysed in all patients who received treatment and submitted adverse event information), assessed at the second interim and final analysis by the masked Data and Safety Monitoring Board. The cutoff for final analysis was 450 patients with 346 deaths. This trial is registered with ClinicalTrials.gov, number NCT00803062.Findings: Between April 6, 2009, and Jan 3, 2012, we enrolled 452 patients (225 [50%] in the two chemotherapy-alone groups and 227 [50%] in the two chemotherapy plus bevacizumab groups). By March 7, 2014, 348 deaths had occurred, meeting the prespecified cutoff for final analysis. The chemotherapy plus bevacizumab groups continued to show significant improvement in OS compared with the chemotherapy-alone groups: 16·8 months in the chemotherapy plus bevacizumab groups versus 13·3 months in the chemotherapy-alone groups (hazard ratio 0·77 [95% CI 0·62-0·95]; p=0·007). Final OS among patients not receiving previous pelvic radiotherapy was 24·5 months versus 16·8 months (0·64 [0·37-1·10]; p=0·11). Postprogression OS was not significantly different between the chemotherapy plus bevacizumab groups (8·4 months) and chemotherapy-alone groups (7·1 months; 0·83 [0·66-1·05]; p=0·06). Fistula (any grade) occurred in 32 (15%) of 220 patients in the chemotherapy plus bevacizumab groups (all previously irradiated) versus three (1%) of 220 in the chemotherapy-alone groups (all previously irradiated). Grade 3 fistula developed in 13 (6%) versus one (<1%). No fistulas resulted in surgical emergencies, sepsis, or death.Interpretation: The benefit conferred by incorporation of bevacizumab is sustained with extended follow-up as evidenced by the overall survival curves remaining separated. After progression while receiving bevacizumab, we did not observe a negative rebound effect (ie, shorter survival after bevacizumab is stopped than after chemotherapy alone is stopped). These findings represent proof-of-concept of the efficacy and tolerability of antiangiogenesis therapy in advanced cervical cancer.Funding: National Cancer Institute. [ABSTRACT FROM AUTHOR]- Published
- 2017
- Full Text
- View/download PDF
16. Highlights from the gynecologic oncology track at the 2017 Annual Meeting of the American Society of Clinical Oncology.
- Author
-
Wolford, Juliet E. and Tewari, Krishnansu S.
- Subjects
- *
OVARIAN cancer treatment , *CERVICAL cancer treatment , *CERVICAL cancer patients - Published
- 2017
- Full Text
- View/download PDF
17. Full-Thickness Skin Grafts for Neovaginal Construction in Mayer-Rokitansky-Küster-Hauser Syndrome.
- Author
-
Tewari, Krishnansu S., Tracy, Lauren, and DiSaia, Philip J.
- Published
- 2015
- Full Text
- View/download PDF
18. Full-Thickness Skin Grafts for Neovaginal Construction in Mayer-Rokitansky-Küster-Hauser Syndrome.
- Author
-
Tewari, Krishnansu S., Tracy, Lauren, and DiSaia, Philip J.
- Subjects
- *
LONGITUDINAL method , *MEDICAL protocols , *SKIN grafting , *MAYER-Rokitansky-Kuster-Hauser syndrome , *GENOTYPES - Abstract
Background: Mayer-Rokitansky-Küster-Hauser (MRKH) syndrome is characterized by vaginal agenesis, the treatment of which typically involves neovaginal construction using split-thickness skin grafts. While successful in many patients, this method may result in vaginal contracture or foreshortening. Neovaginal construction using full-thickness skin grafts (FTSGs) is an underutilized surgical technique associated with decreased rate of contracture and improved functional outcomes. Cases: FTSGs were used for neovaginal construction in 5 patients with MRKH syndrome. This report describes the surgical technique and the current authors' experience when using it. There was a mean follow-up time of 39.4 months (range: 9-111 months). Results: All 5 grafts have remained patent, and all of the patients who desired vaginal intercourse are now capable of achieving this. None of the 5 patients had vaginal contraction or foreshortening. Conclusions: Neovaginal construction using FTSGs is an underutilized and underreported technique in the gynecologic literature. Surgical planning, dilator use, and management of granulation tissue are important considerations when applying this technique. In the current authors' experience, the use of FTSGs in neovaginal construction for patients with MRKH has been successful, with no incidence of vaginal contraction or foreshortening. (J GYNECOL SURG 31:52) [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
19. Exploring the Therapeutic Rationale for Angiogenesis Blockade in Cervical Cancer.
- Author
-
Krill, Lauren S. and Tewari, Krishnansu S.
- Subjects
- *
CLINICAL trials , *CONFIDENCE intervals , *NEOVASCULARIZATION inhibitors , *PAPILLOMAVIRUS diseases , *SURVIVAL , *TUMOR markers , *GENOMICS , *VASCULAR endothelial growth factors , *BEVACIZUMAB , *INVESTIGATIONAL drugs , *PATHOLOGIC neovascularization , *PHARMACODYNAMICS , *THERAPEUTICS ,DISEASE relapse prevention ,CERVIX uteri tumors - Abstract
Purpose: This review highlights the molecular and pathologic evidence that cervical cancer is driven by angiogenesis and presents a summary of the recent clinical research in antiangiogenesis therapy for advanced cervical cancer with a focus on the use of bevacizumab. Methods: The articles chosen for this review reveal the rationale for antiangiogenesis agents in cervical cancer from 3 perspectives: pathologic, molecular, and clinical data. Findings: Several translational investigations have revealed that proangiogenic signaling cascades are active in cervical carcinogenesis and can be used to improve patient outcomes in advanced disease. For example, in a recently published study of patients with recurrent and metastatic cervical cancer, bevacizumab was the first targeted agent to improve overall survival in a gynecologic cancer when successfully combined with 2 different chemotherapy regimens. Implications: Because of recent advances in screening, aggressive management of cervical intraepithelial neoplasia, and human papillomavirus vaccination, cervical cancer is preventable and curable with radical surgery plus lymphadenectomy surgery or chemoradiation plus brachytherapy if detected early. Unfortunately, for patients with metastatic or recurrent disease, effective therapeutic options are limited for this aggressive life-threatening condition. However, molecularly targeted agents have provided a critical opportunity to improve patient outcomes beyond optimizing cytotoxic chemotherapy regimens so that they may benefit from other agents or emergent therapies in the future. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
20. Immunotherapy: An Evolving Paradigm in the Treatment of Advanced Cervical Cancer.
- Author
-
Eskander, Ramez N. and Tewari, Krishnansu S.
- Subjects
- *
PREVENTIVE health services , *IMMUNOTHERAPY , *HUMAN papillomavirus vaccines , *SOCIAL services case management , *HISTORY , *TUMOR treatment ,PAPILLOMAVIRUS disease prevention ,CERVIX uteri tumors - Abstract
Purpose: In 2014, the US Food and Drug Administration approved the first targeted agent, bevacizumab, in the treatment of advanced stage, persistent, or recurrent cervical cancer. This oncologic milestone has catalyzed interest in the investigation of alternate therapies, including immunotherapy, in an effort to extend life and possibly cure patients with advanced stage disease. Methods: This review article focuses on the evolving paradigm of immunotherapy in the treatment of cervical cancer, describing the biologic basis of this treatment modality and discussing applicable Phase I to II clinical trials. Findings: To date several trials have been conducted exploring vaccine-based therapies, adoptive T-cell therapy, and immune-modulating agents in patients with cervical cancer with promising results. Implications: Immunotherapy represents a promising therapeutic paradigm in the treatment of advanced cervical cancer. Additional investigation is warranted to try and identify alternate immune targets and predictors of response, allowing for the selection of patients most likely to benefit from immune-based treatments. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
21. Response to Alexandre Andre B A da Costa et al.
- Author
-
Monk, Bradley J., Coleman, Robert L., Tewari, Krishnansu S., Randall, Leslie M., Pothuri, Bhavana, Slomovitz, Brian M., and Herzog, Thomas J.
- Published
- 2024
- Full Text
- View/download PDF
22. Beyond angiogenesis blockade: targeted therapy for advanced cervical cancer.
- Author
-
Eskander, Ramez N. and Tewari, Krishnansu S.
- Subjects
- *
NEOVASCULARIZATION , *CERVICAL cancer treatment , *CANCER chemotherapy , *RADIATION , *CANCER patients - Abstract
The global burden of advanced stage cervical cancer remains significant, particular in resource poor countries where effective screening programs are absent. Unfortunately, a proportion of patients will be diagnosed with advanced stage disease, and may suffer from persistent or recurrent disease despite treatment with combination chemotherapy and radiation. Patients with recurrent disease have a poor salvage rate, with an expected 5-year survival of less than 10%. Recently, significant gains have been made in the antiangiogenic arena; nonetheless the need to develop effective alternate targeted strategies is implicit. As such, a review of molecular targeted therapy in the treatment of this disease is warranted. In an era of biologics, combined therapy with cytotoxic drugs and molecular targeted agents, represents an exciting arena yet to be fully explored. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
23. Chemotherapy-induced neutropenia as a biomarker of survival in advanced ovarian carcinoma: An exploratory study of the Gynecologic Oncology Group.
- Author
-
Tewari, Krishnansu S., Java, James J., Gatcliffe, Troy A., Bookman, Michael A., and Monk, Bradley J.
- Subjects
- *
CANCER chemotherapy , *NEUTROPENIA , *BIOMARKERS , *OVARIAN cancer , *GYNECOLOGY , *CARBOPLATIN , *THERAPEUTICS - Abstract
Abstract: Objective: To determine whether chemotherapy-induced neutropenia (C-iN) is associated with improved survival in a population of primary advanced ovarian cancer and peritoneal carcinoma patients treated with a carboplatin plus paclitaxel chemotherapy backbone. Methods: A post-hoc exploratory analysis of Gynecologic Oncology Group (GOG) protocol 182 was performed. Landmark analysis was conducted on all patients with progression-free survival >18weeks from the time of study entry. Neutropenia was defined as the absolute neutrophil count <1000mm3. The occurrence of C-iN was analyzed according to demographic, clinicopathologic, and therapeutic intent, including age, body surface area, and treatment arm. Progression-free survival (PFS) and overall survival (OS) were estimated using the Kaplan–Meier method. The Cox proportional hazards model was used to evaluate independent prognostic factors and to estimate their effects on PFS and OS. Results: Neutropenic data was available for 3447 patients. Neutropenic (n=3196) and non-neutropenic groups (n=251) were similar in demographic and clinicopathologic characteristics. Neutropenic patients experienced significantly improved survival compared to non-neutropenic patients with the adjusted hazard ratio (HR) for death being 0.86 (95% confidence interval 0.74–0.99; p=0.041). There was no survival benefit associated with any of the treatment arms among patients with C-iN. Conclusion: These data suggest that C-iN may represent a clinical biomarker associated with a survival advantage for patients with untreated advanced ovarian cancer. The absence of C-iN may indicate under-dosing and ultimately attenuated anti-neoplastic effect in vulnerable populations. [Copyright &y& Elsevier]
- Published
- 2014
- Full Text
- View/download PDF
24. Improved Survival with Bevacizumab in Advanced Cervical Cancer.
- Author
-
Tewari, Krishnansu S., Sill, Michael W., Long III, Harry J., Penson, Richard T., Huang, Helen, Ramondetta, Lois M., Landrum, Lisa M., Oaknin, Ana, Reid, Thomas J., Leitao, Mario M., Michael, Helen E., and Monk, Bradley J.
- Subjects
- *
BEVACIZUMAB , *CANCER chemotherapy , *CERVICAL cancer treatment , *HYPERTENSION , *ADVERSE health care events - Abstract
The article presents a study on the effectiveness of bevacizumab and non-platinum combination chemotherapy in treating cervical cancer. It discusses the methods used in the study, the overall survival of patients who received the combined bevacizumab and chemotherapy, and the association of bevacizumab with hypertension, thrombolic events and gastrointestinal fistulas.
- Published
- 2014
- Full Text
- View/download PDF
25. Incorporation of anti-angiogenesis therapy in the management of advanced ovarian carcinoma—Mechanistics, review of phase III randomized clinical trials, and regulatory implications.
- Author
-
Eskander, Ramez N. and Tewari, Krishnansu S.
- Subjects
- *
NEOVASCULARIZATION , *OVARIAN cancer , *CLINICAL trials , *CANCER chemotherapy , *VASCULAR endothelial growth factors , *MONOCLONAL antibodies - Abstract
Abstract: Despite survival gains achieved nearly two decades ago with combination platinum- and taxane-based intravenous chemotherapy, overall survival curves have remained relatively unchanged during the 21st century using newer cytotoxic agents. Although combined intravenous–intraperitoneal (IV–IP) chemotherapy is promising, tolerability remains a significant issue. An emphasis has been placed on exploring dose dense schedules and targeted agents. Vascular endothelial growth factor (VEGF) has emerged as an important therapeutic target in several solid tumors including ovarian carcinoma. The monoclonal antibody, bevacizumab, binds VEGF, thus preventing activation of the VEGF receptor (VEGFR) leading to inhibition of tumor angiogenesis. To date eight phase 3 randomized controlled trials incorporating anti-angiogenesis therapy in the treatment of newly diagnosed and recurrent ovarian carcinoma have met their primary endpoints. Four of these trials included bevacizumab and were reported from 2010 to 2012. During 2013, the other four studies were reported, each studying one of the following novel anti-angiogenesis agents: pazopanib, cediranib, trebananib, and nintedanib. Importantly, none of these drugs have been approved by the United States Food and Drug Administration (US FDA) for the treatment of ovarian cancer. The purpose of this review will be to highlight both VEGF-dependent and non-VEGF dependent angiogenic pathways in ovarian cancer and discuss the phase 3 experiences and regulatory implications of targeting the tumor microenviroment with anti-angiogenesis therapy. [Copyright &y& Elsevier]
- Published
- 2014
- Full Text
- View/download PDF
26. Association of number of positive nodes and cervical stroma invasion with outcome of advanced endometrial cancer treated with chemotherapy or whole abdominal irradiation: A Gynecologic Oncology Group study
- Author
-
Tewari, Krishnansu S., Filiaci, Virginia L., Spirtos, Nick M., Mannel, Robert S., Thigpen, J. Tate, Cibull, Michael L., Monk, Bradley J., and Randall, Marcus E.
- Subjects
- *
TREATMENT of endometrial cancer , *TREATMENT effectiveness , *DOXORUBICIN , *CISPLATIN , *RANDOMIZED controlled trials , *DISEASE progression - Abstract
Abstract: Objective: To determine whether the number of positive pelvic nodes (PPN), cervical stromal involvement (CSI), and/or lymphovascular space involvement (LVSI) were prognostic factors among women with advanced endometrial carcinoma treated with adriamycin plus cisplatin (AP) or whole abdominal irradiation (WAI). Methods: Data were abstracted from records of patients treated with adjuvant WAI or AP in a GOG randomized trial. Cox proportional hazards models were used to estimate the association of CSI and PPN with differences in PFS and OS while adjusting for treatment and previously studied factors. Results: WAI was randomly allocated to 202 and AP to 194 eligible patients. CSI (n=93 total) was associated with a 44% increase in risk of progression and a 33% increase in risk of death. There was a trend for increasing number PPN being associated with a 7% per positive node increase in risk of progression/death. For CSI, the estimated unadjusted treatment hazard ratios (HRs) were: PFS 0.85 (0.53, 1.38); OS 0.81 (0.50, 1.33). For metastatic disease limited to a single PPN (n=25), the unadjusted HRs were: PFS 0.96 (0.34, 2.74); OS 0.73 (0.24, 2.18). The test of homogeneity of treatment effect (ie., AP vs WAI) across subgroups (CSI, number of positive pelvic nodes) was not statistically significant for either endpoint, thus supporting the superiority of chemotherapy as reported in the original manuscript. Conclusions: The presence of CSI and increasing number of PPN were associated with poor prognosis. On average, patients with CSI experienced improved PFS and OS when treated with AP relative to WAI. [Copyright &y& Elsevier]
- Published
- 2012
- Full Text
- View/download PDF
27. Emerging treatment options for management of malignant ascites in patients with ovarian cancer.
- Author
-
Eskander, Ramez N. and Tewari, Krishnansu S.
- Subjects
- *
OVARIAN cancer , *ASCITES , *DYSPNEA , *ABDOMINAL bloating , *PELVIC pain - Abstract
Malignant ascites affects approximately 10% of patients with recurrent epithelial ovarian cancer and is associated with troublesome symptoms, including abdominal pressure and distension, dyspnea, bloating, pelvic pain, and bowel/bladder dysfunction. To date, no effective therapy has been identified for the treatment of malignant ascites in patients with recurrent, advanced ovarian cancer. In this article, we discuss currently existing options for the treatment of ascites associated with ovarian cancer, and review the literature as it pertains to novel, targeted therapies. Specifically, preclinical and clinical trials exploring the use of the antiangiogenic agents, bevacizumab and vascular endothelial growth factor-trap, as well as the nonangiogenic agent, catumaxomab, will be reviewed. Despite current limitations in treatment, knowledge regarding management options in the palliation of ascites is critical to practicing physicians. Ultimately, as with all novel therapies, symptom relief and treatment goals must be weighed against patient discomfort and potentially significant adverse events. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
28. American Society of Clinical Oncology 2011 Annual Meeting Update: Summary of Selected Gynecologic Cancer Abstracts
- Author
-
Tewari, Krishnansu S. and Monk, Bradley J.
- Published
- 2011
- Full Text
- View/download PDF
29. A feasibility study of topotecan with standard-dose cisplatin and concurrent primary radiation therapy in locally advanced cervical cancer
- Author
-
Gatcliffe, Troy A., Tewari, Krishnansu S., Shah, Amy, Brewster, Wendy R., Burger, Robert A., Kuo, Jeffrey V., and Monk, Bradley J.
- Subjects
- *
CERVICAL cancer treatment , *CISPLATIN , *CANCER radiotherapy , *CANCER chemotherapy , *CANCER patients , *CANCER relapse , *DRUG dosage - Abstract
Abstract: Objectives: Topotecan improves response rate (RR), progression-free survival (PFS) and overall survival (OS) when added to cisplatin in treating metastatic and recurrent cervical cancer. The objective of this study was to assess the feasibility of adding weekly topotecan to cisplatin in patients with primary, locally advanced carcinoma of the cervix receiving pelvic irradiation. Methods: Patients with primary, previously untreated, histologically confirmed invasive squamous cell, adenocarcinoma, or adenosquamous carcinoma of the uterine cervix, stages IB2–IVA were treated with external beam pelvic radiotherapy (45 Gy), intracavitary low dose rate brachytherapy (40 Gy) and a parametrial boost (5.4–9 Gy) with overall treatment time not to exceed 8 weeks. Concurrent chemotherapy was IV cisplatin 40 mg/m2 plus IV topotecan 2 mg/m2 on days 1, 8, 15, 22, 29 and once during parametrial boost for 6 cycles. Patients were monitored with history, physical examination, tumor measurement and laboratory evaluation before entering the study, before each cycle of chemotherapy, at study termination and every three months thereafter. Results: The study met its accrual goal of 12 patients. With a median follow-up of 22 months, eleven patients completed treatment and ten are in long term follow up without evidence of recurrent disease. The 12th patient developed progressive disease during therapy. All patients completed at least 4 cycles of chemotherapy, with the majority (82%) completing 5 or more. Grade 2 or higher neutropenia delayed treatment in 54% of cycles. The median treatment delay was 1.5 cycles (range: 1 to 5 cycles). Median treatment time was 59 days (range 46 to 81 days). The complete RR was 92% (95% confidence interval, 55%–100%). Conclusions: The addition of weekly topotecan to cisplatin at this dose and schedule during pelvic irradiation for locally advanced cervical cancer appears to be feasible. Based on this primary treatment data and the activity of cisplatin–topotecan in the recurrent disease setting, phase II and III studies of this combination are warranted. [Copyright &y& Elsevier]
- Published
- 2009
- Full Text
- View/download PDF
30. Conservation of in vitro drug resistance patterns in epithelial ovarian carcinoma
- Author
-
Tewari, Krishnansu S., Mehta, Rita S., Burger, Robert A., Yu, Ing-Ru, Kyshtoobayeva, Ainura S., Monk, Bradley J., Manetta, Alberto, Berman, Michael L., Disaia, Philip J., and Fruehauf, John P.
- Subjects
- *
DRUG resistance , *OVARIAN diseases , *CANCER patients , *CRYOBIOLOGY - Abstract
Abstract: Purpose. : To compare the in vitro drug resistance profiles of advanced stage primary and recurrent epithelial ovarian cancer specimens using the tritiated thymidine uptake assay. Methods. : Extreme drug resistance (EDR) to cisplatin, paclitaxel, 4-hydroxycyclophosphamide, and topotecan was determined for an unselected population of primary and metastatic malignant ovarian tissues, synchronous tumors (primary and metastatic tissues obtained from the same patient at diagnosis), and metachronous lesions (specimens from the same patient before and after chemotherapy). Results. : For the large unselected population of malignant tissues (total, N = 6990; primary ovarian, N = 2031; metastatic ovarian, N = 4959), no statistically significant differences were discovered between primary tissues and metastatic lesions when a comparison was made between the percentage of tumors from each group that exhibited extreme drug resistance to the agents assayed. From the library of 6990 specimens, 119 synchronous pairings were identified. These synchronous lesions did not differ significantly in the %EDR between primary and metastatic sites in the same patient; approximately 10% shifted between low drug resistance and EDR. A total of 334 metachronous pairings were identified and the percentage of tissues that exhibited EDR also failed to show a significant difference when primary tumors were compared with matched recurrences in the same patient. Conclusions. : For the agents studied, acquired resistance was not a function of disease site. In vitro drug resistance observed at recurrence was not influenced significantly by intervening therapy. It is possible that assay results at diagnosis could be used to guide subsequent therapy at relapse, especially when recurrent tissue is not available for analysis. [Copyright &y& Elsevier]
- Published
- 2005
- Full Text
- View/download PDF
31. Unusual presentation of a malignant granular cell tumor of the pelvis: case report and literature review
- Author
-
Berg, Jena C., Tewari, Krishnansu S., Del Rosario, Raul, and Berman, Michael L.
- Subjects
- *
SOFT tissue tumors ,PELVIS cancer - Abstract
: BackgroundMalignant granular cell tumors are among the rarest of soft tissue cancers, currently understood to be of Schwann cell origin. As with their benign counterparts, malignant granular cell tumors (MGCTs) have a wide anatomic distribution and carry a poor prognosis, with recurrence and metastasis typically within 1 year of diagnosis. Only a handful of MGCTs have been described in the pelvis.: CaseWe describe a case of malignant granular cell tumor that presented as a pararectal mass associated with severe rectal pain. The patient underwent pelvic exenteration and postoperative radiation therapy. She recurred with evidence of liver metastases on imaging studies 8 months following her exenteration.: ConclusionWe discuss the diagnosis and prognosis of malignant granular cell tumors arising in the pelvis. [Copyright &y& Elsevier]
- Published
- 2003
- Full Text
- View/download PDF
32. Treatment of recurrent gynecologic malignancies with iodine-125 permanent interstitial irradiation.
- Author
-
Monk, Bradley J., Tewari, Krishnansu S., Puthawala, Ajmel A., Syed, A. M. Nisar, Haugen, Julie A., and Burger, Robert A.
- Subjects
- *
BOWEL obstructions , *RADIOTHERAPY , *IODINE radioisotopes , *COMPARATIVE studies , *RESEARCH methodology , *MEDICAL cooperation , *OVARIAN tumors , *RADIOISOTOPE brachytherapy , *RESEARCH , *RETROPERITONEUM , *SQUAMOUS cell carcinoma , *ENDOMETRIAL tumors , *EVALUATION research , *RETROSPECTIVE studies , *THERAPEUTICS ,VAGINAL tumors ,CERVIX uteri tumors - Abstract
Purpose: To analyze the outcome of permanent 125I interstitial radiotherapy for unresectable retroperitoneal recurrences of gynecologic malignancies. Methods and Materials: A retrospective review of 20 patients treated between 1979 and 1993 was performed to evaluate survival and morbidity associated with the interstitial 125I technique. Results: Nineteen tumors were located on the lateral pelvic wall and one in the para-aortic region. Eight patients, not previously irradiated, received external beam radiotherapy (EBRT) along with 125I interstitial implants placed at the time of celiotomy. Nineteen (95%) are dead of disease at 1–69 months of follow-up. The median survival was 7.7 months for patients treated with 125I alone and 25.4 months for those treated with both 125I and EBRT. One patient is alive without evidence of disease 69 months after 125I implantation. Fistulas, bowel obstructions, and fatal complications occurred only among patients previously irradiated. Conclusions: When used in a previously irradiated field, 125I interstitial radiotherapy has major morbidity and is unlikely to be associated with cure or long-term survival. In radiotherapy-naive patients with unresectable isolated recurrent gynecologic malignancies, 125I implants and EBRT are feasible and occasionally may contribute to long-term disease-free survival. [Copyright &y& Elsevier]
- Published
- 2002
- Full Text
- View/download PDF
33. Cemiplimab monotherapy in Japanese patients with recurrent or metastatic cervical cancer.
- Author
-
Hasegawa, Kosei, Takahashi, Shunji, Ushijima, Kimio, Okadome, Masao, Yonemori, Kan, Yokota, Harushige, Vergote, Ignace, Monk, Bradley J., Tewari, Krishnansu S., Fujiwara, Keiichi, Li, Jingjin, Jamil, Shaheda, Paccaly, Anne, Takehara, Kazuhiro, Usami, Tomoka, Aoki, Yoichi, Suzuki, Nao, Kobayashi, Yoichi, Yoshida, Yoshio, and Watari, Hidemichi
- Subjects
- *
CANCER chemotherapy , *JAPANESE people , *CEMIPLIMAB , *CERVICAL cancer , *OVERALL survival - Abstract
Background: In the phase 3 EMPOWER‐Cervical 1/GOG‐3016/ENGOT‐cx9 study, cemiplimab significantly improved overall survival (OS) versus chemotherapy for patients with recurrent or metastatic cervical cancer who progressed after first‐line platinum‐based chemotherapy. We present a post hoc subgroup analysis of patients enrolled in Japan. Methods: Patients were enrolled regardless of programmed cell death‐ligand 1 status and randomized 1:1 to cemiplimab 350 mg intravenously every 3 weeks or investigator's choice single‐agent chemotherapy for up to 96 weeks. Primary endpoint was OS. Key secondary endpoints were progression‐free survival (PFS) and objective response rate (ORR). Results: Overall, 608 patients were randomized, of whom 56 (9.2%) were in Japan (cemiplimab, n = 29; chemotherapy, n = 27). The median (range) duration of follow‐up was 13.6 (6.0–25.3) versus 18.2 (6.0–38.2) months for patients in Japan and for the overall population, respectively. Median OS (95% confidence interval [CI]) was 8.4 (7.0‐not evaluable) and 9.4 (5.4–14.9) months for cemiplimab versus chemotherapy (hazard ratio [HR]: 0.86; 95% CI: 0.43–1.68). Median PFS (95% CI) was 4.0 (1.4–8.2) versus 3.7 (1.8–4.2) months with cemiplimab and chemotherapy (HR: 0.90; 95% CI: 0.50–1.61), respectively. ORR was 17.2% for cemiplimab and 7.4% for chemotherapy (odds ratio, 2.47; 95% CI, 0.44–13.99). Incidence of treatment‐emergent adverse events at any grade was 79.3% for cemiplimab and 100% for chemotherapy. Grade ≥3 adverse events were 37.9% versus 66.7% with cemiplimab and chemotherapy, respectively. Discussion: While acknowledging limitations inherent to a small subgroup analysis, the HR of 0.86 observed in Japanese patients suggests an emerging survival benefit despite a 4.6‐month shorter median duration of follow‐up versus the overall study population. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
34. Homologous recombination deficiency should be tested for in patients with advanced stage high-grade serous ovarian cancer aged 70 years and over.
- Author
-
Pitiyarachchi, Omali, Ansell, Peter J., Coleman, Robert L., Dinh, Minh H., Holman, Laura, Leath III, Charles A., Werner, Theresa, DiSilvestro, Paul, Morgan, Mark, Tew, William, Lee, Christine, Cunningham, Mary, Newton, Meredith, Edraki, Babak, Lim, Peter, Barlin, Joyce, Spirtos, Nicola M., Tewari, Krishnansu S., Edelson, Mitchell, and Reid, Thomas
- Subjects
- *
HOMOLOGOUS recombination , *CLINICAL trials , *OLDER patients , *BRCA genes , *AGE groups , *OVARIAN cancer - Abstract
Due to limited data on homologous recombination deficiency (HRD) in older patients (≥ 70 years) with advanced stage high grade serous ovarian cancer (HGSC), we aimed to determine the rates of HRD at diagnosis in this age group. From the Phase 3 trial VELIA the frequency of HRD and BRCA1/2 pathogenic variants (PVs) was compared between younger (< 70 years) and older participants. HRD and somatic(s) BRCA1/2 pathogenic variants (PVs) were determined at diagnosis using Myriad myChoice® CDx and germline(g) BRCA1/2 PVs using Myriad BRACAnalysis CDx®. HRD was defined if a BRCA PV was present, or the genomic instability score (GIS) met threshold (GIS ≥ 33 & ≥ 42 analyzed). Of 1140 participants, 21% were ≥ 70 years. In total, 26% (n = 298) had a BRCA1/2 PV and HRD, 29% (n = 329) were HRD/ BRCA wild-type, 33% (n = 372) non-HRD, and 12% HR-status unknown (n = 141). HRD rates were higher in younger participants, 59% (n = 476/802), compared to 40% (n = 78/197) of older participants (GIS ≥ 42) [ p < 0.001]; similar rates demonstrated with GIS ≥ 33, 66% vs 48% [ p < 0.001]. g BRCA PVs observed in 24% younger vs 8% of older participants (p < 0.001); s BRCA in 8% vs 10% (p = 0.2559), and HRD (GIS ≥ 42) not due to g BRCA was 35% vs 31% (p = 0.36). HRD frequency was similar in participants aged < 70 and ≥ 70 years (35% vs 31%) when the contribution of g BRCA was excluded; rates of s BRCA PVs were also similar (8% v 10%), thus underscoring the importance of HRD and BRCA testing at diagnosis in older patients with advanced HGSC given the therapeutic implications. [Display omitted] • 48% of high grade serous ovarian cancers (HGSC) in older patients are homologous recombination deficient (HRD). • Somatic or germline BRCA1/2 pathogenic variants (PVs) contribute to almost half of HGSC tumors with HRD. • Excluding the contribution of germline BRCA PVs, the frequency of HRD is similar in younger vs older patients with HGSC. • The frequency of somatic BRCA1/2 PVs is independent of age (8% younger v 10% older participants). • HRD testing should not be restricted by patient age. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
35. A systematic review of stage IVA cervical cancer treatment: Challenges in the management of an understudied group.
- Author
-
Hunsberger, Kyra S., Treiman, Sierra, Monk, Bradley J., Tewari, Krishnansu S., Taunk, Neil K., and Chase, Dana M.
- Subjects
- *
CLINICAL trials , *INDUCTION chemotherapy , *ADJUVANT chemotherapy , *CERVICAL cancer , *SURVIVAL rate - Abstract
Stage IVA patients comprise a small proportion of participants in cervical cancer trials, yet survival outcomes are disproportionately poor. We aim to perform a systematic review evaluating stage IVA cervical cancer. This systematic review was completed via PRISMA 2020 guidelines using two databases. Inclusion criteria comprised Phase III trials (2004–2024) assessing stage IVA cervical cancer including patients by stage. Searches had MeSH terms: ((cervical cancer) AND (stage IVA) AND (locally advanced)). 761 were articles identified, including books, trials, reviews, and meta-analyses. Of the articles identified, 12 met inclusion criteria. A total of 133 (3.8% of study populations) stage IVA and 818 (40% of study populations) stage III-IVA cervical cancer patients were analyzed. Two studies (stage IVA n = 15; 3.1%) established cisplatin as chemoradiotherapy agent of choice, while one study (stage IVA n = 2; 1%) showed no benefit with cisplatin versus radiotherapy alone. Four studies (stage IVA n = 32; 3.6%; stages IIIB-IVA n = 220; 24%) found no benefit with adjuvant chemotherapy, with one analyzing stage IIIB-IVA patients (progression-free survival (PFS) hazard ratio (HR) = 0.84; 95% confidence interval (CI): 0.57–1.23). Three studies (stage IVA n = 71; 5%) found no benefit adding immunomodulator (stage IVA overall survival HR = 3.48; 95% CI: 0.52–23.29), hypoxic cell sensitizer, or immunotherapy (stage III-IVA PFS HR = 0.71; 95% CI: 0.49–1.03) to chemoradiotherapy. One study (stages III-IVA n = 598; 56%) found benefit adding immunotherapy to chemoradiotherapy (stage III-IVA PFS HR = 0.58; 95% CI: 0.42–0.8). One study (stage IVA n = 13; 3.5%) showed benefit with induction chemotherapy. Trials have not included substantial IVA patients to draw reasonable conclusions. Despite mixed results for immunotherapy, adjuvant chemotherapy, and induction chemotherapy, the exact benefit for stage IVA patients remains unknown. Future clinical trials should include a greater number of stage IVA cervical cancer patients and analyze them individually. • Stage IVA CC presents with distinctly poor outcomes compared to other stages of LACC. • Standard of care for stage IVA has remained chemoradiotherapy for the last 20 years. • Racial minorities have poor survival outcomes and highest incidence of stage IV CC. • Ongoing clinical trials are likely to lead to changing the standard of care for LACC. • Improving outcomes for the highest risk group (stage IVA) will continue to be important. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
36. New world order(s): Healthcare metrics, international borders, and gravitational waves.
- Author
-
Tewari, Krishnansu S.
- Published
- 2014
- Full Text
- View/download PDF
37. Platinum resistance in gynecologic malignancies: Response, disease free and overall survival are predicted by biochemical signature: A metabolomic analysis.
- Author
-
D'Amora, Paulo, Silva, Ismael Dale C.G., Tewari, Krishnansu S., Bristow, Robert E., Cappuccini, Fabio, Evans, Steven S., Salzgeber, Marcia B., Addis-Bernard, Paula J., Palma, Anton M., Marchioni, Dirce M.L., Carioca, Antonio A.F., Penner, Kristine R., Alldredge, Jill, Longoria, Teresa, and Nagourney, Robert A.
- Subjects
- *
GYNECOLOGIC cancer , *PROGRESSION-free survival , *BRANCHED chain amino acids , *OVERALL survival , *PLATINUM , *SENSITIVITY & specificity (Statistics) - Abstract
Platinum resistance, defined as the lack of response or relapse within six months of platinum-based chemotherapy, is an important determinant of survival in gynecologic cancer. We used quantitative Mass Spectrometry to identify metabolic signatures that predict platinum resistance in patients receiving chemotherapy for gynecologic cancers. In this study 47 patients with adenocarcinoma of the ovary or uterus who were candidates for carboplatin plus paclitaxel submitted blood for quantitation of metabolites and surgical specimens for the isolation 3-dimensional organoids used to measure individual patient platinum resistance, ex vivo. Results were correlated with response, time to progression and survival. Of 47 patients, 27 (64.3%) achieved complete remission with a mean time to progression of 1.9 years (± 1.5), disease-free survival of 1.7 years (± 1.4) and overall survival of 2.6 years (± 1.6) and a mean cisplatin lethal concentration 50% (LC50) = 1.15 μg/ml (range 0.4–3.1). Cisplatin LC50's correlated with a non-significant decrease in complete remission (RR [95% CI] =0.76 [0.46–1.27]), diminished disease-free survival (median: 1.15 vs. 2.99 years, p = 0.038) and with biochemical signatures of 186 metabolites. Receiver operating curves (ROC) of lipid ratios, branched chain amino acids and the tryptophan to kynurenine ratio identified patients at the highest risk of relapse and death (AUC = 0.933) with a sensitivity of 92.0% and specificity of 86.0% (p < 0.001). Metabolic signatures in gynecologic cancer identify patients at the highest risk of relapse and death offering new diagnostic and prognostic tools for management of the advanced gynecologic tumors. [Display omitted] • Platinum resistance in gynecologic cancer correlates with metabolic signatures measured by quantitative mass spectrometry. • Metabolic signatures predict clinical outcome following carboplatin plus Paclitaxel chemotherapy. • Altered amino acid and lipid profiles characterize a state of tumor cellular quiescence associated with immune dysfunction. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
38. Clinical implications for cediranib in advanced cervical cancer.
- Author
-
Tewari, Krishnansu S
- Published
- 2015
- Full Text
- View/download PDF
39. Correlation between Surgeon's assessment and radiographic evaluation of residual disease in women with advanced stage ovarian cancer reported to have undergone optimal surgical cytoreduction: An NRG Oncology/Gynecologic Oncology Group study.
- Author
-
Eskander, Ramez N., Kauderer, James, Tewari, Krishnansu S., Mannel, Robert S., Bristow, Robert E., O'Malley, David M., Rubin, Stephen C., Glaser, Gretchen E., Hamilton, Chad A., Fujiwara, Keiichi, Huh, Warner K., Ueland, Frederick, Stephan, Jean-Marie, and Burger, Robert A.
- Subjects
- *
OVARIAN cancer treatment , *CYTOREDUCTIVE surgery , *CLINICAL drug trials , *BEVACIZUMAB , *COMPUTED tomography - Abstract
Purpose We sought to determine the level of concordance among surgeons' assessment of residual disease (RD) and pre-treatment computed tomography (CT) findings among women who underwent optimal surgical cytoreduction for advanced stage ovarian cancer. Methods This is a post-trial ad hoc analysis of a phase 3 randomized clinical trial evaluating the impact of bevacizumab in primary and maintenance therapy for patients with advanced stage ovarian cancer following surgical cytoreduction. All subjects underwent imaging of the chest/abdomen/pelvis to establish a post-surgical baseline prior to the initiation of chemotherapy. Information collected on trial was utilized to compare surgeon's operative assessment of RD, to pre-treatment imaging. Results Of 1873 enrolled patients, surgical outcome was described as optimal (RD ≤ 1 cm) in 639 subjects. Twelve patients were excluded as they did not have a baseline, pretreatment imaging, leaving 627 participants for analysis. The average interval from surgery to baseline scan was 26 days (range: 1–109). In 251 cases (40%), the post-operative scan was discordant with surgeon assessment, demonstrating RD > 1 cm in size. RD > 1 cm was most commonly identified in the right upper quadrant (28.4%), retroperitoneal para-aortic lymph nodes (RD > 1.5 cm; 28.2%) and the left upper quadrant (10.7%). Patients with RD > 1 cm on pre-treatment CT (discordant) exhibited a significantly greater risk of disease progression (HR 1.30; 95% CI 1.08–1.56; p = 0.0059). Conclusions Among patients reported to have undergone optimal cytoreduction, 40% were found to have lesions >1 cm on postoperative, pretreatment imaging. Although inflammatory changes and/or rapid tumor regrowth could account for the discordance, the impact on PFS and distribution of RD may suggest underestimation by the operating surgeon. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
40. Carboplatin dosing in the treatment of ovarian cancer: An NRG oncology group study.
- Author
-
Praiss, Aaron M., Miller, Austin, Smith, Judith, Lichtman, Stuart M., Bookman, Michael, Aghajanian, Carol, Sabbatini, Paul, Backes, Floor, Cohn, David E., Argenta, Peter, Friedlander, Michael, Goodheart, Michael J., Mutch, David G., Gershenson, David M., Tewari, Krishnansu S., Wenham, Robert M., Wahner Hendrickson, Andrea E., Lee, Roger B., Gray, Heidi, and Secord, Angeles Alvarez
- Subjects
- *
OVARIAN cancer , *CLINICAL trials , *RECEIVER operating characteristic curves , *CARBOPLATIN , *CANCER treatment - Abstract
To determine the effects of using National Comprehensive Cancer Network (NCCN) guidelines to estimate renal function on carboplatin dosing and explore adverse effects associated with a more accurate estimation of lower creatinine clearance (CrCl). Retrospective data were obtained for 3830 of 4312 patients treated on GOG182 (NCT00011986)—a phase III trial of platinum-based chemotherapy for advanced-stage ovarian cancer. Carboplatin dose per patient on GOG182 was determined using the Jelliffe formula. We recalculated CrCl to determine dosing using Modification of Diet in Renal Disease (MDRD) and Cockcroft-Gault (with/without NCCN recommended modifications) formulas. Associations between baseline CrCl and toxicity were described using the area under the receiver operating characteristic curve (AUC). Sensitivity and positive predictive values described the model's ability to discriminate between subjects with/without the adverse event. AUC statistics (range, 0.52–0.64) showed log(CrCl Jelliffe) was not a good predictor of grade ≥3 adverse events (anemia, thrombocytopenia, febrile neutropenia, auditory, renal, metabolic, neurologic). Of 3830 patients, 628 (16%) had CrCl <60 mL/min. Positive predictive values for adverse events ranged from 1.8%–15%. Using the Cockcroft-Gault, Cockcroft-Gault with NCCN modifications, and MDRD (instead of Jelliffe) formulas to estimate renal function resulted in a >10% decrease in carboplatin dosing in 16%, 32%, and 5.2% of patients, respectively, and a >10% increase in carboplatin dosing in 41%, 9.6% and 12% of patients, respectively. The formula used to estimate CrCl affects carboplatin dosing. Estimated CrCl <60 mL/min (by Jelliffe) did not accurately predict adverse events. Efforts continue to better predict renal function. Endorsing National Cancer Institute initiatives to broaden study eligibility, our data do not support a minimum threshold CrCl <60 mL/min as an exclusion criterion from clinical trials. • The formula used to estimate CrCl affects carboplatin dosing. • Estimated creatinine clearance (CrCl) <60 mL/min (by Jelliffe) did not accurately predict adverse events. • Our data do not support a minimum threshold CrCl <60 mL/min as exclusion criteria from clinical trials. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
41. The effect of older age on treatment outcomes in women with advanced ovarian cancer receiving chemotherapy: An NRG-Oncology/Gynecologic Oncology Group (GOG-0182-ICON5) ancillary study.
- Author
-
Sia, Tiffany Y., Tew, William P., Purdy, Christopher, Chi, Dennis S., Menzin, Andrew W., Lovecchio, John L., Bookman, Michael A., Cohn, David E., Teoh, Deanna G., Friedlander, Michael, Bender, David, Mutch, David G., Gershenson, David M., Tewari, Krishnansu S., Wenham, Robert M., Wahner Hendrickson, Andrea E., Lee, Roger B., Gray, Heidi J., Secord, Angeles Alvarez, and Van Le, Linda
- Subjects
- *
CANCER chemotherapy , *OVARIAN cancer , *TREATMENT effectiveness , *PATIENT compliance , *OVARIAN epithelial cancer - Abstract
To assess the effect of age on overall survival (OS) in women with ovarian cancer receiving chemotherapy. Secondary objectives were to describe the effect of age on treatment compliance, toxicities, progression free survival (PFS), time from surgery to chemotherapy, and rates of optimal cytoreduction. Women enrolled in GOG 0182-ICON5 with stage III or IV epithelial ovarian cancer (EOC) who underwent surgery and chemotherapy between 2001 and 2004 were included. Patients were divided into ages <70 and ≥ 70 years. Baseline characteristics, treatment compliance, toxicities, and clinical outcomes were compared. We included a total of 3686 patients, with 620 patients (16.8%) ≥ 70 years. OS was 37.2 months in older compared to 45.0 months in younger patients (HR 1.21, 95% CI, 1.09–1.34, p < 0.001). Older patients had an increased risk of cancer-specific-death (HR 1.16, 95% CI, 1.04–1.29) as well as non-cancer related deaths (HR 2.78, 95% CI, 2.00–3.87). Median PFS was 15.1 months in older compared to 16.0 months in younger patients (HR 1.10, 95% CI, 1.00–1.20, p = 0.056). In the carboplatin/paclitaxel arm, older patients were just as likely to complete therapy and more likely to develop grade ≥ 2 peripheral neuropathy (35.7 vs 19.7%, p < 0.001). Risk of other toxicities remained equal between groups. In women with advanced EOC receiving chemotherapy, age ≥ 70 was associated with shorter OS and cancer specific survival. Older patients receiving carboplatin and paclitaxel reported higher rates of grade ≥ 2 neuropathy but were not more likely to suffer from other chemotherapy related toxicities. Clintrials.gov : NCT00011986 • Age ≥ 70 years was associated with an increased risk of both cancer-related and non-cancer related death. • Carboplatin and paclitaxel administration is well tolerated regardless of age. • Older age was associated with higher rates of grade 2 or higher peripheral neuropathy. • Risks of other chemotherapy related toxicities were equal between older compared to younger patients. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
42. Corrigendum to “American Society of Clinical Oncology 2011 Annual Meeting Update: Summary of Selected Gynecologic Cancer Abstracts” [Gynecol Oncol 122 (2011) 209–212]
- Author
-
Tewari, Krishnansu S. and Monk, Bradley J.
- Published
- 2011
- Full Text
- View/download PDF
43. The spectrum and clinical sequelae of human papillomavirus infection
- Author
-
Monk, Bradley J. and Tewari, Krishnansu S.
- Subjects
- *
CANCER patients , *CANCER in women , *PAPILLOMAVIRUSES , *CERVICAL cancer - Abstract
Abstract: Infection with the human papillomavirus (HPV) is the most common sexually transmitted disease afflicting approximately 80% of the population. HPV infection is an essential factor in cervical carcinogenesis and cervical carcinoma is the second most common cause of cancer among women worldwide. In addition to cervical cancer, other malignancies in both men and women such as esophageal, oropharyngeal, and anal cancer have been causally associated with this virus. Other gender-specific HPV-related cancers include penile, vulvar and vaginal cancer. HPV-16 is the most common HPV type associated with a malignant phenotype regardless of organ of origin. HPV-16 together with HPV-18 accounts for approximately 70% of cervical cancers. Other non-oncogenic HPV types including HPV types 6 and 11 are associated with over 90% of benign HPV-related lesions such as genital warts and juvenile respiratory papillomatosis. [Copyright &y& Elsevier]
- Published
- 2007
- Full Text
- View/download PDF
44. The clinical and prognostic significance of pre-chemotherapy serum CA-125 in high-risk early stage ovarian cancer: An NRG/GOG ancillary study.
- Author
-
Chan, John K., Tian, Chunqiao, Kesterson, Joshua P., Richardson, Michael T., Lin, Ken, Tewari, Krishnansu S., Herzog, Thomas, Kapp, Daniel S., Monk, Bradley J., Casablanca, Yovanni, Hanjani, Parviz, Wenham, Robert M., Walker, Joan, McNally, Leah, Copeland, Larry J., Robertson, Sharon, Lentz, Samuel, Spirtos, Nick M., and Bell, Jeffery G.
- Subjects
- *
CA 125 test , *OVARIAN cancer , *OVARIAN epithelial cancer , *CLINICAL trials , *PROPORTIONAL hazards models , *TUMOR classification - Abstract
To determine the clinical and prognostic significance of CA-125 trends prior to, during, and after chemotherapy in high-risk early-stage epithelial ovarian cancer patients. All patients were enrolled in a phase III randomized trial (GOG 157) following upfront surgery for grade 3 stage IA/IB, stage IC, or stage II disease, and had been treated with either three or six cycles of carboplatin/paclitaxel. Kaplan-Meier method and Cox proportional hazards model were used to evaluate recurrence-free survival (RFS) and overall survival (OS). Of 350 patients, the median pre-chemotherapy CA-125 was 65 (IQR: 31–129). 71% of Whites had an elevated CA-125 compared to 47% of non-Whites (p = 0.006). Following the first cycle of chemotherapy, 74% of those with elevated CA-125 had normalization. Those who had normalization of CA-125 after 1 cycle had significantly better 5-year RFS (81% vs. 65%, p = 0.003) and OS (87% vs. 75%, p = 0.009) compared to those who did not normalize (defined as ≤35 U/mL). The pattern of CA-125 change following chemotherapy cycle 1, from normal to normal vs. elevated to normal vs. elevated to elevated had corresponding RFS of 87% vs. 80% vs. 68% (p = 0.013), and OS of 92% vs. 88% vs. 77% (p = 0.009). However, the percent decline (p = 0.993) and absolute nadir normal value of CA-125 (0–10 vs. 11–35 U/mL) were not predictive of outcome (p = 0.4). Normal baseline CA125 and normalization of this biomarker after the first cycle of chemotherapy were associated with better survival in high-risk early-stage epithelial ovarian cancer patients. • Normal baseline CA125 prior to chemotherapy is associated with better survival in high-risk early-stage ovarian cancer. • Normalization of CA125 after the first cycle of chemotherapy is associated improved survival in early-stage ovarian cancer. • Percent decline and absolute nadir normal value of CA125 were not predictive of outcome in early-stage ovarian cancer. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
45. What proportion of patients with stage 3 ovarian cancer are potentially cured following intraperitoneal chemotherapy? Analysis of the long term (≥10 years) survivors in NRG/GOG randomized clinical trials of intraperitoneal and intravenous chemotherapy in stage III ovarian cancer
- Author
-
Pitiyarachchi, Omali, Friedlander, Michael, Java, James J., Chan, John K., Armstrong, Deborah K., Markman, Maurie, Herzog, Thomas J., Monk, Bradley J., Backes, Floor, Secord, Angeles Alvarez, Bonebrake, Albert, Rose, Peter G., Tewari, Krishnansu S., Lentz, Samuel S., Geller, Melissa A., Copeland, Larry J., and Mannel, Robert S.
- Subjects
- *
OVARIAN cancer , *CANCER fatigue , *OVARIAN epithelial cancer , *CLINICAL trials , *SURVIVAL rate , *SURVIVAL analysis (Biometry) , *OVERALL survival - Abstract
Patients with advanced epithelial ovarian cancer (EOC) alive without progression at a landmark time-point of 10 years from diagnosis are likely cured. We report the proportion of patients with Stage III EOC who were long-term disease-free survivors (LTDFS≥10 years) following either intraperitoneal (IP) or intravenous (IV) chemotherapy as well as the predictors of LTDFS. Data from 3 mature NRG/GOG trials (104, 114, 172) were analyzed and included demographics, clinicopathologic details, route of administration, and survival outcomes of patients living ≥10 years assessed according to the Kaplan-Meier method. Cox regression survival analysis was performed to evaluate independent prognostic predictors of LTDFS. Of 1174 patients randomized, 10-year overall survival (OS) was 26% (95% CI, 23–28%) and LTDFS ≥10 years was 18% (95% CI, 16–20%). Patients with LTDFS ≥10 years had a median age of 54.6 years (p < 0.001). Younger age (p < 0.001) was the only independent prognostic factor for LTDFS≥10 years on multivariate Cox analysis. Approximately 18% of patients were LTDFS ≥10 years. They form the tail end of the survival curve and are likely cured. Our results provide a comparative benchmark to evaluate the impact of PARP inhibitors in 1st line maintenance trials on survival outcomes. • Long term survivors with advanced ovarian cancer are uncommon and include patients alive with or without disease recurrence • Clinical trials don't report the patients who are long term disease free survivors (LTDFS ≥10 years) and likely cured • Almost 20% of patients were LTDFS ≥10 years in GOG trials of intravenous vs intraperitoneal chemotherapy • Apart from younger patient age at diagnosis there were no other factors associated with LTDFS ≥10 years [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
46. Impact of veliparib, paclitaxel dosing regimen, and germline BRCA status on the primary treatment of serous ovarian cancer – an ancillary data analysis of the VELIA trial.
- Author
-
Aghajanian, Carol, Swisher, Elizabeth M., Okamoto, Aikou, Steffensen, Karina Dahl, Bookman, Michael A., Fleming, Gini F., Friedlander, Michael, Moore, Kathleen N., Tewari, Krishnansu S., O'Malley, David M., Chan, John K., Ratajczak, Christine, Hashiba, Hideyuki, Wu, Meijing, Dinh, Minh H., and Coleman, Robert L.
- Subjects
- *
OVARIAN cancer , *BRCA genes , *PACLITAXEL , *PROPORTIONAL hazards models , *DATA analysis , *GERM cells - Abstract
In the Phase 3 VELIA trial (NCT02470585), veliparib added to carboplatin plus paclitaxel concomitantly and as maintenance for women with newly-diagnosed advanced ovarian cancer significantly improved progression-free survival (PFS) versus chemotherapy alone. Here we present exploratory analyses by paclitaxel dosing schedule and germline BRCA (g BRCA) status. Women with untreated ovarian carcinoma were randomized (1:1:1) to: veliparib during chemotherapy and maintenance (veliparib-throughout), veliparib during chemotherapy followed by placebo maintenance (veliparib-combination only), or placebo during chemotherapy and maintenance (control). Chemotherapy included carboplatin plus dose-dense (DD; weekly) or every-3-week (Q3W) paclitaxel (a stratification factor at randomization), selected at the investigator's discretion pre-randomization. PFS was assessed by paclitaxel dosing schedule using a Cox proportional hazard model adjusted by treatment arm and stratification factors; safety was analyzed based on paclitaxel dosing schedule and g BRCA status. 1132 patients were analyzed by paclitaxel schedule. Pooled treatment arms demonstrated longer median PFS with DD (n = 586) versus Q3W (n = 546) paclitaxel (ITT: 20.5 vs 15.7 months, hazard ratio [HR] 0.77; homologous recombination proficient cancer: 15.1 vs 11.8 months, HR 0.64; BRCA wt: 18.0 vs 12.9 months, HR 0.70). Comparison between arms favored veliparib-throughout versus control in both DD (PFS, 24.2 vs 18.3 months, hazard ratio 0.67) and Q3W (19.3 vs 14.6, hazard ratio 0.69) subgroups. DD paclitaxel was associated with higher incidence of Grade 3/4 neutropenia, fatigue, and anemia versus Q3W. There were no differences in toxicity between g BRCA m (n = 211) and g BRCA wt (n = 902) subgroups. DD paclitaxel was tolerable and associated with longer PFS in the HR proficient and g BRCA wt groups, versus Q3W. g BRCA status did not impact safety. • Weekly (compared to every 3 weeks) paclitaxel was associated with longer PFS in HRP and BRCA wt cohorts • PFS was improved with veliparib compared with control regardless of paclitaxel dosing schedule • In general, grade 3/4 adverse events were more common in dose-dense paclitaxel groups compared with every-3-week paclitaxel • Germline BRCA status showed no impact on incidences of adverse events across arms [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
47. Patient reported outcomes for cisplatin and radiation followed by carboplatin/paclitaxel versus carboplatin/paclitaxel for locally advanced endometrial carcinoma: An NRG oncology study.
- Author
-
Matulonis, Ursula A., Huang, Helen Q., Filiaci, Virginia L., Randall, Marcus, DiSilvestro, Paul A., Moxley, Katherine M., Fowler, Jeffrey M., Powell, Matthew A., Spirtos, Nick M., Tewari, Krishnansu S., Richards, William E., Nakayama, John M., Mutch, David G., Miller, David S., Matei, Daniela, and Wenzel, Lari B.
- Subjects
- *
PATIENT reported outcome measures , *ENDOMETRIAL cancer , *PACLITAXEL , *CISPLATIN , *CARBOPLATIN - Abstract
Chemotherapy plus radiation (Cis-RT + CP) did not demonstrate superiority in prolonging relapse-free survival compared to chemotherapy alone in patients with stage III or IVA endometrial carcinoma. The impact of treatment on quality of life (QOL), neurotoxicity (NTX) and psychometric properties of the gastrointestinal (GI) symptoms subscale during treatment and up to 1 year are described herein. QOL assessments were scheduled at baseline, 6 weeks (post completion of RT (Cis-RT + CP) or prior to cycle 3 (CP)), then 18 weeks (end of treatment) and 70 weeks (1 year after the end of treatment) after starting treatment. QOL instruments included the FACT-En TOI, FACT/GOG-neurotoxicity (Ntx) subscale (short), and the gastrointestinal (GI) symptoms subscale. At the end of treatment, patients receiving Cis-RT + CP reported a statistically significant decreased QOL when compared to CP. The decline in QOL was reflected in physical well-being, functional well-being, and endometrial cancer specific concerns, but the minimally important differences (MID) were not considered clinically meaningful. Patients in both groups reported increased chemotherapy-induced Ntx symptoms with the CP group having worse scores and reaching peak symptoms at the time of chemotherapy completion. Patients on Cis-RT + CP reported statistically significantly worse GI symptoms after radiation therapy compared to patients on CP, this occurred across assessment intervals, though the MID was not meaningful. Psychometric evaluations indicated that the GI symptom scale is reliable, valid, and responsive to change. PROs indicate that the chemoradiotherapy group experienced worse HRQoL and GI toxicity compared to patients randomized to chemotherapy alone for locally advanced endometrial cancer though based on the MID, these were not clinically meaningful differences. The GI symptom subscale was a reliable and valid scale that has value for future trials. Trial registration: NCT00942357 • Radiation/chemotherapy caused more QOL and GI symptoms versus chemotherapy; the differences were not clinically meaningful. • Both treatment groups experienced neuropathy, especially in the chemotherapy group. • The differing toxicities of the 2 arms can assist clinicians in counseling patients given the efficacy equivalence. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
48. Prognostic significance of ethnicity and age in advanced stage epithelial ovarian cancer: An NRG oncology/gynecologic oncology group study.
- Author
-
duPont, Nefertiti C., Enserro, Danielle, Brady, Mark F., Moxley, Katherine, Walker, Joan L., Cosgrove, Casey, Bixel, Kristin, Tewari, Krishnansu S., Thaker, Premal, Wahner Hendrickson, Andrea E., Rubin, Stephen, Fujiwara, Keiichi, Casey, A. Catherine, Soper, John, Burger, Robert A., and Monk, Bradley J.
- Subjects
- *
OVARIAN epithelial cancer , *GYNECOLOGIC oncology , *PROPORTIONAL hazards models , *ASIANS , *ETHNICITY - Abstract
Age and ethnicity are among several factors that influence overall survival (OS) in ovarian cancer. The study objective was to determine whether ethnicity and age were of prognostic significance in women enrolled in a clinical trial evaluating the addition of bevacizumab to front-line therapy. Women with advanced stage ovarian, primary peritoneal, or fallopian tube cancer were enrolled in a phase III clinical trial. All women had surgical staging and received adjuvant chemotherapy with one of three regimens. Cox proportional hazards models were used to evaluate the relationship between OS with age and race/ethnicity among the study participants. One-thousand-eight-hundred-seventy-three women were enrolled in the study. There were 280 minority women and 328 women over the age of 70. Women age 70 and older had a 34% increase risk for death when compared to women under 60 (HR = 1.34; 95% CI 1.16–1.54). Non-Hispanic Black women had a 54% decreased risk of death with the addition of maintenance bevacizumab (HR = 0.46, 95% CI:0.26–0.83). Women of Asian descent had more hematologic grade 3 or greater adverse events and a 27% decrease risk of death when compared to non-Hispanic Whites (HR = 0.73; 95% CI: 0.59–0.90). Non-Hispanic Black women showed a decreased risk of death with the addition of bevacizumab and patients of Asian ancestry had a lower death rate than all other minority groups, but despite these clinically meaningful improvements there was no statistically significant difference in OS among the groups. • Non-Hispanic black women had a decreased risk of death with upfront and maintenance bevacizumab. • Women of Asian ancestry had a decreased risk of death when compared to white women. • Native Asian women had a longer median overall survival rate when compared to American women of Asian ancestry. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
49. Symptoms of Women With High-Risk Early-Stage Ovarian Cancer.
- Author
-
Chan, John K., Tian, Chunqiao, Kesterson, Joshua P., Monk, Bradley J., Kapp, Daniel S., Davidson, Brittany, Robertson, Sharon, Copeland, Larry J., Walker, Joan L., Wenham, Robert M., Casablanca, Yovanni, Spirtos, Nick M., Tewari, Krishnansu S., and Bell, Jeffrey G.
- Subjects
- *
OVARIAN epithelial cancer , *OVARIAN cancer , *PROPORTIONAL hazards models , *SYMPTOMS , *ABDOMINAL pain , *PELVIC pain , *OVARIES , *RESEARCH , *OVARIAN tumors , *CLINICAL trials , *RESEARCH methodology , *RETROSPECTIVE studies , *EVALUATION research , *COMPARATIVE studies , *RANDOMIZED controlled trials , *RESEARCH funding , *EARLY diagnosis - Abstract
Objective: To assess the presentation, characteristics, and prognostic significance of symptoms in patients with high-risk early-stage epithelial ovarian cancer.Methods: A retrospective chart review was performed on all patients enrolled in a phase III clinical trial (GOG 157). All patients had surgically staged, high-risk early-stage epithelial ovarian cancer (stage IA-IB and grade 3, any clear cell, stage IC or II). Chi-square and Kaplan-Meier estimates and Cox proportional hazards models were used for statistical analyses.Results: Of 419 patients evaluated for symptoms, 301 (72%) presented with one or more symptoms, and 118 (28%) were asymptomatic but had a mass found on examination. Forty percent had only one symptom, and 32% had more than one symptom. Among those with at least one symptom, the most common were abdominal and pelvic pain (31%), and increased girth or fullness (26%). Overall, 23% of patients with tumors 10 cm or smaller, 27% of patients with tumors larger than 10 cm to 15 cm, and 46% of patients with tumors larger than 15 cm had multiple symptoms (P<.001). There was no significant difference in presentation of symptoms based on age, stage, or histologic subtype. Symptoms at diagnosis were not associated with recurrence or survival.Conclusion: More than 70% of patients with high-risk early-stage, epithelial ovarian cancer present with one or more symptoms, with the most common being abdominal or pelvic pain. The proportion of women with symptoms and the number of symptoms increase with enlarging tumor size. [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
50. Visual inspection with acetic acid screening for cervical cancer among women receiving anti‐retroviral therapy for human immunodeficiency virus infection in northern Tanzania.
- Author
-
Chinn, Justine O., Runge, Ava S., Dinicu, Andreea I., Chang, Jenny, Maher, Justine A., Crawford, Elizabeth W., Naaseh, Ariana, Cooper, Emma C., Zezoff, Danielle C., White, Kayla M., Lucas, Alexa N., Bera, Kevin R., Bernstein, Megan, Hari, Anjali, Ziogas, Argyrios, Tewari, Sujata E., Pearre, Diana C., and Tewari, Krishnansu S.
- Subjects
- *
HIV infection epidemiology , *HIV-positive persons , *COLD therapy , *EARLY detection of cancer , *FISHER exact test , *HIGHLY active antiretroviral therapy , *ACETIC acid , *CHI-squared test , *DESCRIPTIVE statistics ,CERVIX uteri tumors - Abstract
Aim: To evaluate visual inspection with acetic acid (VIA) screening for cervical cancer among human immunodeficiency virus (HIV)‐positive patients in an East African community. Methods: During a July 2018 cervical cancer screen‐and‐treat in Mwanza, Tanzania, participants were offered free cervical VIA screening, cryotherapy when indicated, and HIV testing. Acetowhite lesions and/or abnormal vascularity were designated VIA positive in accordance with current guidelines. The association between VIA results and HIV status was compared using Chi‐square and Fisher exact tests. Results: Eight hundred and twenty‐four of 921 consented participants underwent VIA screening and 25.0% (n = 206) were VIA positive. VIA‐positive nonpregnant women (n = 147) received cryotherapy and 15 (1.8%) with cancerous‐appearing lesions were referred to Bugando Hospital. Sixty‐six women were HIV‐positive and included 25 diagnosed with HIV at the cervical cancer VIA screening and 41 with a prior diagnosis of HIV who were receiving antiretroviral therapy (ART) at the time of cervical cancer VIA screening. Sixty‐four of these 66 patients, were screened with VIA. HIV infection was not associated with VIA findings. Abnormal VIA positive screening was observed in 20.3% (n = 13) of HIV‐positive patients and in 24.4% (n = 145) of HIV‐negative patients (p = 0.508). A nonsignificant trend of higher VIA positive screens among newly diagnosed HIV patients of 26.1% (n = 6) versus patients with preexisting HIV on ART of 17.1% (n = 7) was observed (p = 0.580). Conclusion: The unexpected lack of correlation between HIV infection and VIA positivity in a community with access to ART warrants additional research regarding the previously described role of ART in attenuating HPV‐mediated neoplasia. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.